AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Sam Altman-backed Apex Security in advanced talks to be acquired by Varonis for up to $40M
2
"Everyone will be a manager" - what the world of work will look like with AI agents
3
Facial recognition firm Oosto, formerly AnyVision, sold for $125M after raising $352M
4
What went wrong at AnyVision? Lessons from a $352M flameout
5
"Wiz is the world's fastest-growing cyber company and together we can build the largest security company to come out of Israel"
More news

Cancer

8 stories about Cancer
מייסד קייט פארמה אריה בלדגרין

Gilead Builds on Kite Pharma Acquisition, Buys Second CAR-T Therapy Company

10.12.17|Lilach Baumer
California-based Cell Design Labs will be acquired in a deal valued at up to $567 million
המדען הראשי ב כלל ביוטכנולוגיה ד"ר ג'וליאן אדמס

Pharma Veteran Julian Adams takes Helm at Gamida Cell

21.11.17|Lilach Baumer
The Novartis-backed company is developing a universal bone marrow transplant solution for patients unable to find a donor
דרור חרץ מנכ"ל VBL

VBL Therapeutics Aims to Raise $18.75 Million in Public Offering

20.11.17|Lilach Baumer
The cancer treatment company announced an offering of 2.5 million shares last week
default image

Pontifax Leads $9.5 Funding Round for Biopharmaceutical Company ArQule

19.11.17|CTech
Nasdaq-listed ArQule develops treatments for cancer and rare diseases
default image

Generic Focus made Kite Pharma Founder Leave Teva

13.11.17|Dror Reich
Founder of cancer treatment company sold to Gilead Sciences for $12 billion, says Gilead wants “to crack the cancer market"
default image

Cancer Treatment Company Negotiating $20-25 Million Capital Injection

29.10.17|Lilach Baumer
The potential investors condition the investment on delisting BioCanCell from the Tel Aviv Stock Exchange
default image

Kite Pharma’s Cancer Drug Gets Regulatory Nod

19.10.17|Lilach Baumer
The cancer-treatment company, bought by Gilead Science in August for $11.9 billion, will sell one treatment course of the drug for $373,000
מוסף שבועי 14.9.17 פרופ' גידי גרוס

Kite Pharma Sale Triggers Scientist Quarrel

02.10.17|Zohar Shahar Levy
Zelig Eshhar who patented the company’s core technology is now being sued by his former PhD student and current pharma entrepreneur
Previous Articles